Parecoxib

Summary

Parecoxib (CHEMBL1206690) is an approved small-molecule cyclooxygenase 2 inhibitor (ATC M01AH04); indicated across 5 conditions including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M01AH04
• Indications: 5 conditions
• Clinical trials: 49
• Chemistry: 370.4 Da · C19H18N2O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1206690
Name	Parecoxib
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	119828
ChEBI	CHEBI:73038
ATC	M01AH04
Molecular formula	C19H18N2O4S
Molecular weight	370.4
InChIKey	TZRHLKRLEZJVIJ-UHFFFAOYSA-N

SMILES: CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C

IUPAC name: N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide

ChEBI definition: An N-acylsulfonamide resulting from the formal condensation of valdecoxib with propionic acid. It is a prodrug for valdecoxib.

Pharmacological roles (ChEBI): cyclooxygenase 2 inhibitor, non-narcotic analgesic, non-steroidal anti-inflammatory drug, prodrug.

Also known as: Parecoxib, Rayzon, SC-69124, Xapit, PARECOXIB, Parecoxib sodiumÊ, Parecoxib sodiumÂ, PARECOXIB SODIUM

Parent form; salt/anhydrous children: CHEMBL296913

Patent coverage: 5,530 distinct patent families (22,031 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prostaglandin G/H synthase 2, Nuclear receptor subfamily 4 group A member 2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGS2	8.3	IC50	5	nM	CHEMBL_ACT_18936146

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 49.

Phase distribution

Phase	Trials
PHASE4	23
Not specified	13
PHASE3	9
PHASE2	3
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06600282	PHASE4	NOT_YET_RECRUITING	Bioequivalence of Two Formulations of Parecoxib in Healthy Volunteers Under Fasting Conditions
NCT00346268	PHASE4	TERMINATED	Morphine-Sparing Efficacy Of Parecoxib In Pain Treatment After Radical Prostatectomy
NCT00435747	PHASE4	WITHDRAWN	Efficacy And Safety Of Parecoxib IV/IM 40 Mg Vs Placebo Following Sub Muscular Breast Augmentation
NCT00553605	PHASE4	COMPLETED	Efficacy And Safety Of Parecoxib 40mg vs. Ketoprofen 100mg In The Management Of Acute Renal Colic
NCT00660855	PHASE4	TERMINATED	A Multicenter, Open Label Trial To Evaluate Pain Relief With Intravenous Followed By Oral Therapy With Parecoxib/Valdecoxib 40 Mg/Day For Treatment Of Post-Laparoscopic Surgery Pain
NCT00785863	PHASE4	COMPLETED	Modulation of Remifentanil-induced Postinfusion Hyperalgesia
NCT01186159	PHASE4	COMPLETED	The Correlation of COX-2 Expression in Human Polymorphonuclear Leukocytes/Macrophages (PMNL/MP) and Postoperative Pain
NCT01221025	PHASE4	UNKNOWN	Effect Study of Parecoxib to Treat Emergence Delirium and Postoperative Pain
NCT01361789	PHASE4	COMPLETED	COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined
NCT01526525	PHASE4	COMPLETED	Perioperative Electroacupuncture on Postoperative Analgesia in Prostatectomy
NCT01843010	PHASE4	COMPLETED	Effect of Parecoxib on the Change of Shoulder Pain Threshold After Gynecological Laparoscopies
NCT01859585	PHASE4	COMPLETED	Efficacy Parecoxib and Ketorolac as Preemptive Analgesia in Spine Fusion
NCT01930318	PHASE4	UNKNOWN	Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery
NCT02198924	PHASE4	COMPLETED	Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients
NCT02204878	PHASE4	UNKNOWN	Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy
NCT02272660	PHASE4	COMPLETED	Parecoxib for Pain Management After Total Knee Arthroplasty and Total Hip Arthroplasty
NCT02569905	PHASE4	COMPLETED	Effect of Parecoxib Sodium and Flurbiprofen Injection on Postoperative Shivering
NCT02729935	PHASE4	COMPLETED	Parecoxib for Treatment of Catheter Related Bladder Discomfort
NCT03135795	PHASE4	UNKNOWN	The Epigenetic Modification in OPRM1 on Postoperative Analgesia and Side Effect Induced by Sufentanil
NCT03704623	PHASE4	COMPLETED	Parecoxib vs Paracetamol in the Treatment of Acute Renal Colic
NCT04034836	PHASE4	UNKNOWN	Parecoxib as an Adjuvant to Scalp Nerve Blocks for Relief of Post-craniotomy Pain
NCT05150431	PHASE4	COMPLETED	Optimized Acute Pain Control With Parecoxib in Uniportal Video-assisted Thoracoscopic Surgery.
NCT06140238	PHASE4	COMPLETED	Preemptive Analgesic Efficacy of Parecoxib for Reducing Postoperative Pain in Gynecological Surgery
NCT06315920	PHASE3	NOT_YET_RECRUITING	Analgesic Effect of Parecoxib Versus Morphine in SCD Patients Presenting to the Emergency Department
NCT00139646	PHASE3	TERMINATED	Parecoxib in Renal Colic
NCT00143169	PHASE3	COMPLETED	Morphine-Sparing Effect And Safety Of Parecoxib Administered Intravenously For The Treatment Of Postoperative Pain
NCT00636064	PHASE3	COMPLETED	A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery
NCT00651300	PHASE3	TERMINATED	A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery
NCT01311804	PHASE3	UNKNOWN	An Efficacy and Safety Study of Periarticular Parecoxib Sodium for Pain Management in Total Knee Arthroplasty
NCT02185924	PHASE2/PHASE3	COMPLETED	Combination of Continuous Femoral Block and Intravenous Parecoxib For Postoperative Analgesia After Total Knee Arthroplasty
NCT02749409	PHASE3	TERMINATED	Early Parecoxib Usage to Decreases Narcotic Requirement and Length of Stay After Traumatic Rib Fracture
NCT03059238	PHASE3	COMPLETED	Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
NCT03480165	PHASE3	COMPLETED	The Efficacy of 20 mg Parecoxib as an Adjunct to 0.75% Ropivacaine in Supraclavicular Brachial Plexus Block for Upper Limb Surgery
NCT06579274	PHASE2	NOT_YET_RECRUITING	Evaluation of the Safety and Efficacy of Parecoxib in Patients With Subarachnoid Hemorrhage
NCT06623513	PHASE2	NOT_YET_RECRUITING	Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis
NCT01288924	PHASE2	COMPLETED	Can Parecoxib Reduce Post-operative Ipsilateral Shoulder Pain?
NCT06721988	Not specified	NOT_YET_RECRUITING	Effect of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chronification of Acute Post-operative Pain
NCT07116304	Not specified	NOT_YET_RECRUITING	Comparative Efficacy of IV Parecoxib vs Lidocaine in Reducing Propofol Injection Pain
NCT00763997	Not specified	COMPLETED	Study of the Effect of Dipyrone, Ibuprofen, Paracetamol and Parecoxib on the Platelet Aggregation in Analgetic Dosages
NCT01393925	Not specified	COMPLETED	Effect of Parecoxib on Postoperative Shoulder Pain After Gynecological Laparoscopy.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).